Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09IYM
|
|||
| Former ID |
DIB002324
|
|||
| Drug Name |
AT13148
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Astex pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H16ClN3O
|
|||
| Canonical SMILES |
C1=CC(=CC=C1C2=CNN=C2)C(CN)(C3=CC=C(C=C3)Cl)O
|
|||
| InChI |
1S/C17H16ClN3O/c18-16-7-5-15(6-8-16)17(22,11-19)14-3-1-12(2-4-14)13-9-20-21-10-13/h1-10,22H,11,19H2,(H,20,21)/t17-/m0/s1
|
|||
| InChIKey |
IIRWNGPLJQXWFJ-KRWDZBQOSA-N
|
|||
| CAS Number |
CAS 1056901-62-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Rho-associated protein kinase (ROCK) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01585701) Phase I Study of AT13148, a Novel AGC Kinase Inhibitor. U.S. National Institutes of Health. | |||
| REF 2 | Company report (Astex) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.